Trinity Financial Advisors LLC Abb Vie Inc. Transaction History

Trinity Financial Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$137.6 - $154.97 $287,446 - $323,732	-2,089 Reduced 61.68%	1,298 $201,000
Q3 2023 Oct 18, 2023	SELL	$133.59 - $154.65 $100,726 - $116,606	-754 Reduced 18.21%	3,387 $504,000
Q2 2023 Jul 20, 2023	SELL	$132.51 - $164.9 $122,041 - $151,872	-921 Reduced 18.19%	4,141 $557,000
Q1 2023 Apr 10, 2023	BUY	$144.61 - $166.54 $108,602 - $125,071	751 Added 17.42%	5,062 $806,000
Q4 2022 Jan 20, 2023	BUY	$138.31 - $165.87 $39,003 - $46,775	282 Added 7.0%	4,311 $0
Q3 2022 Oct 24, 2022	BUY	$134.21 - $153.93 $540,732 - $620,183	4,029 New	4,029 $541,000

4,095

1.28B

16.7M

15M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $357B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Trinity Financial Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Trinity Financial Advisors LLC with notifications on news.